Retatrutide Beat Tirzepatide. Here's What I'd Do.

I lost 80 lbs on tirzepatide over 2 years. Now retatrutide's Phase 3 data just dropped, and I keep wondering: would I have lost it faster on this?

Lilly's TRIUMPH-1 trial just published the numbers on retatrutide, a triple agonist that hits GIP, GLP-1, AND glucagon. The top dose data is the kind of result that doesn't come around often.

In this short I break down what TRIUMPH-1 actually showed, the surprising 4 mg dose results, and what this means if you're already at goal on Wegovy or tirzepatide vs if you're stalled on max-dose tirz.

The honest answer about who should care about retatrutide and who shouldn't.

📌 NEW SHORT EVERY DAY covering the GLP-1 and peptide news that actually matters.

🎯 Want a doctor who's actually been on these meds and reads the literature for you? Book a free consult at https://barrickhealth.com

📚 The GLP-1 Bible is available for preorder now: https://barrickhealth.com (everything I tell my patients in one place)

—

ABOUT DR. BARRICK
Dr. Clete Barrick MD is board-certified in internal medicine and obesity medicine, U.S. Navy veteran, and founder of Barrick Health, a concierge telehealth practice operating across 40 states + DC. He's treated 5,000+ patients on GLP-1 medications and lost 80 lbs on tirzepatide himself.

Subscribe for the data that matters. New short every day, full news show every Friday.

—

SOURCES
Eli Lilly TRIUMPH-1 Phase 3 topline results (May 21, 2026)
https://investor.lilly.com/news-releases

—

DISCLAIMER: This content is for educational purposes only and does not constitute medical advice. Always consult with your physician before starting, stopping, or changing any medication or treatment plan.

#GLP1 #Retatrutide #Shorts

Видео Retatrutide Beat Tirzepatide. Here's What I'd Do. канала Barrick Health